Citigroup’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-754,909
| Closed | -$36.2M | – | 7870 |
|
|
2020
Q1 | $36.2M | Sell |
754,909
-991,587
| -57% | -$46.1M | 0.03% | 477 |
|
|
2019
Q4 | $82M | Buy |
1,746,496
+1,694,524
| +3,260% | +$74.9M | 0.06% | 306 |
|
|
2019
Q3 | $1.23M | Sell |
51,972
-2,997
| -5% | -$88.8K | ﹤0.01% | 3411 |
|
|
2019
Q2 | $1.65M | Buy |
54,969
+51,260
| +1,382% | +$1.17M | ﹤0.01% | 3079 |
|
|
2019
Q1 | $84K | Buy |
3,709
+582
| +19% | +$12.5K | ﹤0.01% | 5916 |
|
|
2018
Q4 | $57K | Buy |
3,127
+45
| +1% | +$706 | ﹤0.01% | 6135 |
|
|
2018
Q3 | $56K | Buy |
+3,082
| New | +$36.5K | ﹤0.01% | 6437 |
|
|
2018
Q2 | – | Sell |
-2,225
| Closed | -$11K | – | 7820 |
|
|
2018
Q1 | $11K | Buy |
2,225
+2,037
| +1,084% | +$14.6K | ﹤0.01% | 7034 |
|
|
2017
Q4 | $2K | Buy |
188
+186
| +9,300% | +$2.29K | ﹤0.01% | 7433 |
|
|
2017
Q3 | $0 | Sell |
2
-124
| -98% | -$1.87K | ﹤0.01% | 7555 |
|
|
2017
Q2 | $2K | Buy |
126
+21
| +20% | +$474 | ﹤0.01% | 7073 |
|
|
2017
Q1 | $2K | Sell |
105
-8,158
| -99% | -$156K | ﹤0.01% | 7035 |
|
|
2016
Q4 | $125K | Buy |
+8,263
| New | +$112K | ﹤0.01% | 5636 |
|
Other funds holding RARX
Citigroup's RARX Position: Q2 2020 in Review
Citigroup sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 754,909 shares — an estimated $36.2M sold.
Citigroup first reported a position in RARX in Q4 2016 and held it in 13 quarters. The position peaked at $82M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- Citigroup reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- Citigroup sold 754,909 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $36.2M.
- Citigroup first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 13 quarters.
- Citigroup's Ra Pharmaceuticals, Inc. Common Stock position peaked at $82M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on Citigroup's 13F filing for Q2 2020, filed 12 Aug 2020.